Related Experiment Video
Updated: May 12, 2026

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Natural polysaccharides in colloidal drug delivery systems for brain glioma therapy: Mechanisms and advancements
Chun Li1, Weining Ma2, Haitao Shen3
1Department of Pediatrics, Shengjing hospital of China Medical University, Shenyang 110004, China.
Abstract:
Brain gliomas, particularly glioblastoma (GBM), are a category of brain tumors that are challenging to treat and characterized by low survival rates. Despite improvements in existing treatment options, challenges such as drug resistance, tumor heterogeneity, and the impediment of the blood-brain barrier to effective drug delivery remain prevalent. In recent years, natural polysaccharide polymers have attracted increasing interest in the treatment of GBM owing to their biocompatibility and potential for targeted delivery. Polysaccharides exert their effects through multiple mechanisms, including the modulation of the tumor microenvironment, targeted delivery, immune regulation, and participation in controlled drug release systems, potentially enhancing the adaptability of chemotherapy and extending patient survival. Additionally, this review examines colloidal parameters and biointerface interactions-such as particle size, surface charge, hydrophilic-hydrophobic balance, and membrane adsorption-that govern nanocarrier stability and BBB penetration efficiency. The development of drug delivery platforms based on natural polysaccharides can effectively address the challenges associated with drug delivery, reducing toxicity to healthy tissues. This article evaluates advancements in the use of natural polysaccharides, including hyaluronic acid, chitosan, cellulose, alginate, and starch, in the treatment of brain glioma. It underscores their significant role in eliciting anti-tumor effects and facilitating drug delivery systems, with particular emphasis on the mechanistic contributions of these polysaccharides in drug delivery processes.
Insights
Natural polysaccharides offer promising solutions for brain glioma treatment by enhancing drug delivery and reducing toxicity. These biocompatible polymers show potential in overcoming challenges like drug resistance and the blood-brain barrier.
Area of Science:
- Biomaterials Science
- Oncology
- Nanotechnology
Background:
- Brain gliomas, including glioblastoma (GBM), present significant treatment challenges due to drug resistance, tumor heterogeneity, and the blood-brain barrier (BBB).
- Existing therapies have limited efficacy, necessitating novel approaches for improved patient outcomes and survival rates.
Purpose of the Study:
- To review the advancements in utilizing natural polysaccharides for brain glioma treatment.
- To evaluate the role of polysaccharides in drug delivery systems and their anti-tumor effects.
- To analyze how colloidal properties influence nanocarrier stability and BBB penetration.
Main Methods:
- Literature review of natural polysaccharides (hyaluronic acid, chitosan, cellulose, alginate, starch) in GBM therapy.
- Analysis of polysaccharide mechanisms: tumor microenvironment modulation, targeted delivery, immune regulation, and controlled release.
- Examination of colloidal parameters (particle size, surface charge, etc.) and biointerface interactions impacting nanocarrier performance.
Main Results:
- Natural polysaccharides demonstrate biocompatibility and potential for targeted drug delivery to brain tumors.
- These polymers facilitate multi-mechanistic anti-tumor effects and can be integrated into controlled drug release systems.
- Understanding colloidal parameters is crucial for optimizing nanocarrier stability and BBB penetration for enhanced efficacy.
Conclusions:
- Natural polysaccharides represent a promising class of materials for developing advanced drug delivery platforms for brain gliomas.
- Their application can overcome key therapeutic challenges, reduce systemic toxicity, and potentially improve patient survival.
- Further research into polysaccharide-based nanocarriers holds significant potential for innovative GBM treatments.
More Related Videos
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Related Concept Videos
Secondary Active Transport
Secondary Active Transport
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: